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ABSTRACT 
 
An investigational clinical research study was conducted at an academic healthcare center 
evaluating memantine as an adjunct to opioid therapy for treatment of chronic low back 
pain. The N-Methyl-D-Aspartate (NMDA) receptor is located in pain signaling neuronal 
synapses of the central nervous system.  The receptor binds the excitatory 
neurotransmitter glutamate in addition to NMDA, to increase the magnitude of the 
perception of pain. Memantine (Namenda
©
) is a highly tolerated NMDA receptor 
antagonist which is currently prescribed in the treatment of Alzheimer’s disease. The 
purpose of the non-randomized pilot study without placebo was to evaluate the use of 
adding memantine as an adjunctive pain medication to the regimen of patients who use an 
oxycodone/acetaminophen combination daily for treatment of chronic low back pain 
(LBP). The effect of Memantine was evaluated using diaries where patients record on a 
daily basis the amount of oxycodone/acetaminophen used, pain scores, and number of 
bowel movements. Data was to be collected for six weeks with a two-week preliminary 
phase, followed by a four-week treatment phase, and then analyzed. The objective is to 
evaluate, on a preliminary basis, whether patients benefit from addition of memantine to 
their daily oxycodone/acetaminophen treatment by increased analgesia, a reduction of 
oxycodone/acetaminophen used, and less constipation. Consequently, limitations to the 
process of clinical research in an academic healthcare center are evaluated as a result of 
reduced protected time for researchers and lack of patient participation. 
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INTRODUCTION 
 
Chronic pain has debilitating effects for patients across the United States, causing 
decreased quality of life, as well as increased disability and health-care related costs. 
Estimates of the prevalence of chronic pain reveals that 20% to 60% of the population are 
affected; the disparity in estimates is due to varied techniques employed to identify such 
patients, as well as substantial diversity among study populations and reporting formats 
(Clark, 2002). Chronic low back pain (LBP) is defined as persistent or fluctuating pain in 
and around the lumbar region that has persisted for a period over six months; 60% of 
patients with LBP seek a family physician for treatment (Last & Hulbert, 2009).  In 2009, 
LBP was determined to be the second leading cause of disability in US adults, with total 
costs estimated to be between $100 billion to $200 billion annually, resulting from lost 
productivity and wages, as well as increasing healthcare related costs (Freburger et al., 
2009).  In many regards, it would prove most difficult to measure accurately the 
prevalence of nonspecific chronic LBP because of the ambiguity of causality in the 
population and varied diagnoses. Most studies focus on pharmacological or physiological 
treatments used by the population to manage the pain and subsequent outcomes. Most 
commonly, chronic LBP is treated via self-administration, where individuals monitor 
their own perception of pain and take prescribed medications to provide pain relief in the 
outpatient setting.  
Within the past two decades, the proliferation and increased use of long-term 
opioid therapies and the associated epidemic of opioid abuse, misuse, and overdose have 
caused great concern leading to a more cautious approach to chronic pain management 
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and better monitoring of opioid use for patients with chronic pain (Korff, Kolodny, Deyo, 
& Chou, 2011). In addition, there remains a broad range of socio-economic effects of 
chronic LBP that may be evaluated through psychological, financial, and community 
considerations.   
The persistence of pain influences domains such as depression by increasing fear 
of amplified pain and reduced confidence in the ability to perform daily activities (Slade, 
Molloy, & Keating, 2012). As a result, chronic LBP is associated with reduced 
productivity, availability to work, and increased financial stress leading to an elevated 
economic burden. Chronic LBP may affect an entire family and community; for example, 
an affected individual may not be able to pick up a child, complete household chores, or 
partake in other responsibilities associated with daily life. Currently, there is a broad 
range of interventions for management of chronic lower back pain, with a diversity of 
specialists approaching treatment through varied pharmacological and physical practices. 
Approximately 90% of chronic LBP patients in primary care cannot attribute the 
pain to a specific cause, such as an infection, tumor, or fracture, making treatment for the 
disabling non-specific pain a difficult process (Lee, 2010). As a result of telephone 
surveys of a representative population of 4437 households in 1992 and 5357 households 
in 2006 in North Carolina, the prevalence of chronic LBP increased over a 14 year period 
from 3.9% to 10.2%; these data indicate that approximately 80% of the population is 
expected to suffer from LBP at some point in their lives, with 95% of these patients 
recovering within a few months from onset, and the remaining 5% continuing to suffer 
with chronic LBP (Freburger et al., 2009). As a consequence of the increasing prevalence 
and incidence of chronic LBP, healthcare professionals seek to incorporate evidence-
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based medicine to improve identification of beneficial treatments and translate research 
findings to reduce pain and suffering associated with chronic LBP. 
From a pharmacological standpoint, the first-line therapy for patients with chronic 
LBP is acetaminophen due to a high safety profile.  Non-steroidal anti-inflammatory 
drugs (NSAIDs) are also commonly used due to their similar pain relief; however they 
frequently induce side-effects of a gastrointestinal or renovascular nature (Last & 
Hulbert, 2009). In a recent systematic review of 12 publications regarding the efficacy of 
pharmacological treatments for chronic LBP, NSAIDs such as aspirin, ibuprofen, and 
naproxen are recommended as the first-line of therapy due to their comparable 
effectiveness and lack of the serious side effects that are associated with opioids (White, 
Arnold, Norvell, Ecker, & Fehlings, 2011).  
Opioid analgesics continue to be used extensively for analgesia in patients with 
mild to chronic pain. Opiates are naturally occurring alkaloids from the resin of the 
opium poppy, Papaver somniferum, and include morphine and codeine. Semi-synthetic 
opioids include oxymorphone, oxycodone and methadone. Regardless of the structure of 
such molecules, all opioids display the same basic pharmacological properties by binding 
to opioid receptors to reduce the perception of pain (Yaksh T.L., 2011).   
Oxycodone, similar to morphine, produces analogous side effects involving 
nausea, vomiting, sedation, pruritus, and others, which are usually tolerated within few 
days of initial use; however, oxycodone-induced constipation (as occurs with all opioids) 
persists and usually requires additional medication, such as laxatives or stool softeners, 
for relief (Astolfi, 2011).  This opioid is a useful oral analgesic for treatment of moderate 
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to severe, acute or persistent pain, and is usually combined with acetaminophen or 
ibuprofen, in immediate-release or controlled-released formulations (Baumann TJ, 2011). 
Recently, concerns of associated acetaminophen-induced hepatotoxicity warrant 
investigations to reduce the use of pain medications that combine oxycodone and 
acetaminophen, such as Percocet
©
. In addition, the rise of abuse among opiates such as 
oxycodone necessitates further research into adjunctive medications which may reduce 
the amount of pain medication required for analgesia.  
In addition to the efficacy of prescribing analgesics, many patients are also treated 
pharmacologically for the psychological impacts of chronic LBP. The comorbidity of 
depression and chronic LBP is high; patients who are treated for the pain and depression 
together have better outcomes than those treated for pain alone (Lee, 2010).  Patients 
coping with chronic LBP may develop behaviors to avoid pain or develop increased pain-
related stress to cope with poor treatment outcomes and increasing disability. 
Antidepressants have been found to be no more effective than placebo for treating the 
pain associated with chronic LBP; however, they may be indicated to treat psychosocial 
outcomes such as anxiety and/or depression associated with a chronic pain state (White et 
al., 2011). In most cases, the complexity in which chronic LBP affects each individual is 
different; physicians must consider complementary treatments for the diversity of 
comorbid diseases or disorders that can present in patients. 
There are many non-pharmacological complementary or alternative interventions 
for patients suffering from chronic LBP ranging from hands-on treatments such as 
osteopathic manipulative treatment (OMT), chiropractic adjustments, massage, and 
acupuncture, to practices such as exercise therapy, behavior therapy, yoga, and 
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meditation that prove beneficial in the management of pain. In most cases, 
multidisciplinary rehabilitation including a physician and at least one additional 
intervention reduces pain and alleviates disability to provide benefits lasting for years; 
patients frequently use non-pharmacologic treatments with or without consulting their 
physician (Last & Hulbert, 2009). Many of these methods aim to relieve the pain and 
stress of chronic LBP and increase self-awareness in the patient; each patient must be 
thoroughly evaluated to determine what type of complementary treatment may result in a 
favorable outcome. 
Many investigations have been made into adjunctive medications that may reduce 
the side effects and tolerance produced by long-term opioid use. The demand for 
adjunctive medications in pain therapy is increasing, promoting investigations for 
innovative approaches to management of this condition.  Therapeutic benefits could 
include reduction of opiate use, severity of dependence, and associated side effects.  
Identification of receptors in the pain signaling pathway has led to use of this information 
to increase efficacy of pain therapies.  Some investigations of the role of NMDA-receptor 
antagonists in neuropathic pain have been promising; however there is limited research 
on the effects of these medications on patients who self-manage their chronic pain with 
opioids, as well as some conflicting evidence on benefits of added medication (Gustin et 
al., 2010; Weich et al., 2004). 
The most commonly prescribed opioids are combined with acetaminophen for 
increased analgesia in pain management (Baumann TJ, 2011). Recently, increased 
concerns from the FDA and the healthcare community warranted investigation of 
hepatotoxicity associated with acetaminophen. A review of studies involving 
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opioid/acetaminophen combinations found that no conclusions could be made in regards 
to role of acetaminophen in acute liver failure; recommendations were made for further 
investigation since the impact of removal of these medications would substantially 
impact many patients in the management of pain (Michna et al., 2010).   
Currently, the escalation of opioid misuse and abuse affirms investigations into 
adjunctive medications that can reduce the amount of opioids used for analgesia. This 
warrants the question: is there another class of drug that can provide increased analgesia 
for chronic pain and reduce the amount of opioid combination pain medications a patient 
must take to relieve their pain? In addition, will this drug further benefit the patient by 
reducing the intolerable side effects of opioid therapies?  
In this study, the benefits of adding memantine (Namenda
©
), an N-Methyl-D-
Aspartate (NMDA) receptor antagonist, to a daily regimen of oxycodone/acetaminophen 
(Percocet
©
) will be evaluated in patients with chronic LBP. The NMDA receptor is 
located in the pain signaling neuronal synapses of the central nervous system that bind 
the excitatory neurotransmitter glutamate in addition to NMDA, and is believed to 
increase the magnitude of the perception of pain. Therefore, by blocking this receptor, the 
perception of pain may be reduced, and less medication would be needed for analgesia. 
Memantine is a highly tolerated NMDA receptor antagonist with neuro-protective 
qualities and is currently prescribed in the treatment of Alzheimer’s disease.  The 
proposed benefits of memantine as adjunctive pain medication are being investigated by 
determining if (1) patients take less opioid pain medication for daily analgesia, and (2) 
whether there is a reduction in opioid induced side effects such as constipation. 
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LITERATURE REVIEW 
 
In the central nervous system, glutamate is an abundant excitatory 
neurotransmitter, occupying upwards of 90% of synapses; the N-Methyl-D-Aspartate 
(NMDA) receptor is an ionotropic receptor that binds glutamate in addition to the 
selective agonist NMDA in transmitter-gated and voltage-gated properties (Nolte, 2009).  
The NMDA receptors are found in addition to traditional glutamate receptors on the 
postsynaptic membrane; as well as allowing passage of Na
+ 
and K
+
, the NMDA receptor 
channel allows passage of Ca
2+
, a property associated with long-term potentiation (LTP) 
(Nolte, 2009). The activation of NMDA receptors is therefore necessary to induce LTP, 
which is the prolonged increase (hours to days) in the magnitude of post-synaptic 
response to presynaptic stimulus (Molinoff, 2011). In the pain processing neurons of the 
dorsal horn, both µ-opioid receptors and NMDA-receptors are present at the origins of 
the ascending pathways, and the association of these receptors has proposed 
investigations into the role of NMDA-receptor antagonists, and their role in reducing 
opioid-induced hyperalgesia and tolerance (Price DD, 2000). Hyperalgesia results from 
the combined release of substance P and glutamate in the nociceptive afferents in the 
spinal cord, causing increased activation of the NMDA receptors, and this wind-up 
progressively increases activity in pain transmission (Barrett KE, 2012). Together, the 
increased responsiveness of LTP in the CNS leading to hyperalgesia and allodynia, and 
the increased synaptic plasticity of wind-up, are proposed to be part of the diversity of 
mechanisms which lead to central sensitization and chronic pain (Chizh, 2007).  
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In vivo microdialysis and immunohistochemical analyses have been performed to 
investigate chronic tendinosis of the patellar tendon (Jumper’s knee) of five patients 
against a control group in 2001 (Alfredson, Forsgren, Thorsen, & Lorentzon, 2001). The 
study results revealed the increased presence of glutamate and NMDA receptors in 
patients who suffer with chronic pain without signs of inflammation, a fact which 
warrants future investigations regarding the role of NMDA receptors in peripheral pain 
pathways (Alfredson et al., 2001). Accumulating evidence signifies the role of the 
NMDA-receptor in the peripheral and central processing of nociceptive and neuropathic 
pain and how the activation of the NMDA receptor may increase the perception of pain. 
Recent studies involving the role of N-Methyl-D-Aspartate (NMDA) receptor 
antagonists have produced interesting evidence for the role of blocking this receptor and 
subsequent attenuation of pain. Ketamine, a well-known NMDA receptor antagonist, has 
been used clinically for many years in the treatment of pain in the inpatient setting; 
however, ketamine produces many side effects. The parent analogue of ketamine is 
phencyclidine (PCP); both of these drugs are referred to as “dissociative anesthetics,” 
causing altered states of consciousness, hallucinations, and other central effects which 
limit the clinical use of ketamine (Chizh, 2007). The many limitations of ketamine 
include the fact that a steady state equilibrium blockade of NMDA receptors is difficult to 
achieve with a half-life of 15 minutes, and that the only routes of administration are 
intravenously or intramuscularly (Gilling, Jatzke, Hechenberger, & Parsons, 2009).  
Memantine (Namenda
©
) is the only antiglutamatergic NMDA-antagonist 
currently on the market and is approved in the treatment of Alzheimer disease. 
Memantine retains 100% bioavailability, as it is not biotransformed by the liver, and has 
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been well tolerated by patients in clinical trials, with the most common adverse effects 
being constipation, confusion, dizziness, headache, hallucinations, coughing, and 
hypertension (Slattum PW, 2011). In addition, memantine displays a long half-life, 
ranging from 60 to 80 hours (Slattum PW, 2011) Although memantine and ketamine 
display similar IC50 (half maximal inhibitory concentration) values and kinetics, the 
difference in the related side effects may be the result of ‘partial trapping’ of memantine 
versus ‘full trapping’ of ketamine. Nearly all the ketamine molecules remain trapped in 
the channel of the NMDA receptor following removal of the agonist, whereas some of 
the memantine molecules unbind and become untrapped; this may be due to memantine 
binding to a superficial site, as well as to a deep site in the channel (Kotermanski S, 
2009).  For this reason, memantine has been proposed to be of significance for clinical 
use due to oral efficacy, onset twice as fast, long half-life, and lack of associated side 
effects compared to ketamine (Gilling et al., 2009).   
Studies investigating the benefits of NMDA receptor antagonists in combination 
with opioid therapies have revealed mixed results; some have used animal models in 
attempts to determine effects while other human studies are limited in their small sample 
size, lack of control group, and no placebo or blindedness to yield valid conclusions. 
With strength of research design, a randomized double-blind crossover trial of eight 
patients with chronic phantom limb pain (PLP) in 2004 concluded that the addition of 
memantine over four weeks (first week, 10mg/d; second week, 20mg/d; third and fourth 
weeks, 30mg/d) was ineffective for treatment of chronic PLP (Wiech et al., 2004).  Other 
smaller open study clinical investigations evaluated the addition of memantine for a 
variety of pain conditions and reported contrasting results. Case reports of two 
10 
 
amputation patients with chronic PLP who received high dose opioids revealed a 
substantial decrease in pain intensity shortly after the addition of memantine to their daily 
regimens (Hackworth, Tokarz, Fowler, Wallace, & Stedje-Larsen, 2008). An unpublished 
pilot investigational study on three geriatric patients taking a daily regimen of 
oxycodone/acetaminophen combination for non-specific chronic pain revealed that the 
addition of memantine allowed patients to reduce the amount of pain medications needed 
for analgesia (Galluzzi & Goldstein 2009). For the most part, human studies involving 
memantine for analgesia have been limited in sample size and scale to present inferential 
results. 
In addition to clinical studies evaluating analgesia, investigations have been made 
in regard to neuropathic mechanisms associated with NMDA receptor antagonists and the 
perception of pain. A double-blind randomized placebo-controlled study was performed 
using fMRI with memantine combined with morphine for patients with complex regional 
pain syndrome (CRPS) to revealed reduction in somatosensory-discriminative aspects of 
pain in cS1 and  S2, which is presumed to be associated with the NMDA receptors, in 
addition to decreased activation in the anterior cingulate cortex (ACC), which also occurs 
with opioid therapy (Gustin et al., 2010). In like manner, an open study involving six 
patients with complex regional pain syndrome (CRPS) evaluated the effects of adding 
memantine following an established two week baseline; following eight weeks of 
memantine treatment, fMRI results concluded that the treatment normalized cortical 
reorganization associated with neuropathic pain, and that patients had significantly 
reduced perceived pain intensity at both eight weeks and six months following the 
addition of memantine (Sinis et al., 2007). Another investigation highlighted the 
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relationship of NMDA receptor antagonists and the development of opiate dependence in 
rodents; this study indicated that memantine was effective in reducing morphine-induced 
withdrawal hyperalgesia (Harris, Rothwell, & Gewirtz, 2008). Therefore, NMDA 
receptor antagonists may be useful to prevent or treat opioid dependence in humans, in 
addition to reducing the amount of pain medication to provide analgesia.   
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METHODS 
Sample 
The 6-week pilot study was designed to study 10 patients who take an 
oxycodone/acetaminophen combination (e.g., Percocet
©
) daily for chronic low back pain. 
Potential study subjects were recruited by their primary care physicians at an academic 
community healthcare center. These subjects were 18 years of age or older, displayed 
chronic lower back pain for a minimum of two months, and were taking stable doses of 
an oxycodone/acetaminophen combination for a minimum of six months.  
 Exclusion criteria were patients who were pregnant or planned to become 
pregnant, had a life expectancy less than 6 months, displayed moderately severe 
Alzheimer disease, moderate dementia, depression, and renal or hepatic disease. 
Furthermore, patients were excluded if they were currently taking NMDA-receptor 
antagonists, tricyclic antidepressants, antipsychotics, antiparkinson, or other possibly 
contradictory medications to avoid interactions with the memantine that may cause 
adverse effects to the subject or potentially influence the findings of the study. 
During this study, participants were required to fill out daily diaries in which they 
wrote down their daily intake of an oxycodone/acetaminophen combination, a numeric 
score (0-10) of their pain perception in the morning, afternoon, and evening, and their 
number of bowel movements each day. Therefore, subject compliance was necessary. In 
addition, general weekly questions on the diaries involved causes for additional pain, 
added daily medications, as well as improvements in bowel movements. Participants 
were also required to come to the healthcare center at four sequential appointments on 
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specific days over the 6-week experimental period during the study, so they had to have 
transportation and the physical ability to maintain the visits. 
Research Design 
Approval was granted through the Institutional Review Board (IRB) at 
Philadelphia College of Osteopathic Medicine (PCOM). Before commencement of this 
study, certification of all participating researchers was achieved through the on-line 
Collaborative Institutional Training Initiative (CITI).  Courses completed included the 
Biomedical Investigators Basic Refresher, Health Information Privacy and Security 
(HIPS) for Clinical Investigators, and Good Clinical Practice.  Certification was 
mandatory for investigators performing clinical research involving human subjects to 
educate researchers on proper clinical practice and protection of the subjects’ private 
health information. 
Following IRB approval, patient study packets were prepared for initial 
recruitment which included a copy of the dated and approved informed consent 
document, the first two weeks of diaries, and a study schedule. Following initial 
identification of potential participants, the primary care physician recruited and discussed 
the study with the patients, gave a copy of the informed consent to the patient for review, 
and set up a pre-study visit. At the following visit, participants who signed the informed 
consent were screened for dementia and cognitive impairment by completing a Mini-
mental state examination (MMSE), as well as tested for the presence of depression with a 
short-form Geriatric depression scale (GDS). If required, a pregnancy test would also be 
administered at this pre-study visit. After obtaining a signed informed consent and 
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passing inclusion tests, the subject took home and completed the diaries for Weeks 1 and 
2. The first two weeks acted as a control where each subject established a baseline prior 
to the treatment phase. After 14 days, the subject returned to the clinic with the 
completed diaries, and was given a sample pack of memantine (Namenda
©
) and diaries 
for Weeks 3 and 4. At this point, the patient was instructed to begin 5 mg in the morning 
for Week 3, and then 5 mg in the morning and 5 mg in the evening for Week 4. After 28 
days, the subject returned to the clinic with the completed diaries, was given diaries for 
Weeks 5 and 6 and instruction to continue with the sample pack, taking 10 mg in the 
morning and 5 mg in the evening for Week 5, and 10 mg in the morning and 10 mg in the 
evening for Week 6 .During each week of the study, subjects were contacted by phone to 
ensure compliance with the diaries and medication. 
Instrumentation/Statistical Analysis 
Study subjects were required to fill out diaries where they recorded a numeric 
score of their pain perception in the morning, afternoon, and evening, the total number of 
Percocet© taken each day, as well as the number of bowel movements each day. In 
addition, there are general weekly questions on the diary sheets that involve causes for 
additional pain, added daily medications, as well as improvements in bowel movements. 
Pain intensity was evaluated on a visual analogue scale (VAS) from 0-10 and recorded by 
patients in daily diaries throughout a six week period; first two weeks (Week 1 and Week 
2) served as a control to establish baseline, and following four weeks were the treatment 
phase with increasing titration of memantine. After the first two weeks, the initial 
treatment with medication began in Week 3 and continued through Week 6 with the 
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following doses: Week 3, 5mg a.m.; Week 4, 5mg a.m. and 5mg p.m.; Week 5, 10mg 
a.m. and 5mg p.m.; Week 6, 10mg a.m. and 10mg p.m. 
 In addition, study subjects indicated the number of bowel movements each day to 
determine if the addition of memantine also reduced opioid-induced constipation. The 
data collected was averaged by day for the baseline and treatment phase to be plotted in a 
time course of pain rating (VAS) over time (day). 
 Since this study failed to obtain the total of ten subjects, statistical analysis could 
only be performed on the one subject who completed the study. If the study would have 
been successful in obtaining ten patients, descriptive statistics for each individual 
participant was to include measures of central tendency in numerical and graphical 
summaries. The alternative hypothesis (HA) states that the addition of memantine will 
reduce the perception of pain corresponding to a reduction in the amount of Percocet
©
 
used.  The null hypothesis (H0) states that the addition of memantine will have no effect 
on the perception of pain or amount of Percocet
©
 used.  Individual subjects pre- and post-
treatment were to be tested by a dependent Student’s t-test to evaluate whether treatment 
with memantine correlated with reduced VAS pain perception and 
oxycodone/acetaminophen use from control Weeks 1 and 2, to treatment Weeks 3 
through 6, as well as if the number of bowel movements improved. Collectively, the data 
was to be evaluated through analysis of variance (ANOVA) to evaluate the effects of the 
added medication with VAS pain intensity, amount of oxycodone/acetaminophen used, 
and number of bowel movements. The hypotheses would have been tested at a level of 
significance less than or equal to 0.05. 
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Validity 
As a pilot study, research design and sample size was to be limited to ten patients 
due to availability of patient base, inclusion/exclusion criteria, and ability for 
investigators to commit sufficient time to research endeavors.   
 In addition, reliance on the patients to self-report daily with diary entries at home 
leads to concerns of adherence as well as experimental mortality, with multiple testing 
effects as a result of three daily observations for a period of six weeks. Experimenter 
interaction effects must be considered due to the limited number of researchers and 
participants. This study was designed to investigate and contribute to understanding of an 
opioid adjunctive treatment and its effect on individual participants rather than 
generalizing the sample results to a population.  
Ethical Considerations 
Throughout this study, investigators and researchers involved maintained 
adherence to measures to protect the private healthcare information of all patients and 
study subjects. Only after recruitment from the primary care physicians did the researcher 
have contact with the patients. At all times, the researcher remained objective in 
interactions with patients involved in the study to reduce bias and the potential to 
influence results. 
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RESULTS 
 
Recruitment of patients encompassed a period of six months; six patients were 
identified as potential study subjects based off inclusion criteria. Patient One was the only 
subject to progress through the control phase and subsequently complete the treatment 
phase (Figure 1).  
 
       Figure 1. Recruitment flow chart. 
Two of the six recruited patients were removed from the study by the researcher 
due to failure to meet inclusion criteria. Patient Two failed the GDS. To be included, 
participants must have had a score ≤ 5; this potential subject scored 7. When discussing 
the GDS score, Patient Two also stated some concerns about recent heart problems (atrial 
fibrillation) which caused additional stress. Although the participant was initially willing 
to commit to the study, Patient Two agreed with removal from the study and thought that 
Patients Recruited by Primary Care Physicians (6) 
Removed by investigator (3) 
Noncompliant with 
preliminary schedule (1) 
Work schedule conflict (1) 
Missed appointments (1) 
Excluded (2) 
Failed GDS/MMSE (1) 
Medication Conflict (1) 
 
Completed study (1) 
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it was not the right time to commit to such an endeavor. Patient Three was prescribed 
gabapentin (Neurontin
©
) by another physician which listed as an exclusion criteria on the 
IRB application. Although Patient Three was enthusiastic about participating, this 
participant was removed from the study.   
Three patients encountered complications with participation and were not 
included in the study. Patient Four began the two-week control phase after passing the 
inclusion tests, but was physically and emotionally unable to continue.  Recent 
complications from a fall and family problems at home caused this individual visible 
distress; this participant was crying during the appointment and felt overwhelmed with 
the commitment to the study and was consequently removed. Patient Five was recruited 
and signed the informed consent but could not participate due to a work schedule which 
would not allow the required appointments. Patient Six began the two-week control phase 
but was also unable to maintain regular appointment and did not show for a scheduled 
and rescheduled appointment on the same day.  In addition, Patient Six stated concerns 
about additional daily medication added to the daily regimen which may have influenced 
motivation to participate since this individual was taking multiple prescriptions. This 
concern was discussed at the initial visit; Patient Six inspected the sample pack of 
Namenda
©
 and determined that the additional medication would not be an issue since the 
dosage gradually increased through preset amounts. 
Another factor contributing to the limited recruitment of patients was the 
promotion of the Principal Investigator from Medical Director of the Healthcare Center 
where the study took place, to another position which limited the investigator’s time in 
the healthcare center to recruit patients as needed. Although another primary care 
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physician/investigator continued to recruit when the Principal Investigator was not 
available, schedule constraints and limited protected time prevented recruitment of 
eligible participants.  
Patient One, a 70 year old female with history of chronic low back pain was 
recruited by the Investigator/Primary care physician during a normally scheduled 
appointment based on inclusion criteria and daily use of acetaminophen/oxycodone 
combination (Percocet
©
 5mg/325mg).  This patient was enthusiastic to participate in the 
study due to her high admiration of her primary care physician. The patient returned to 
the office to review and sign the informed consent, and to take the short-form GDS and 
MMSE administered by the researcher. During this appointment, the patient was 
instructed on how to complete the diaries including the Visual Analog Scale (VAS) for 
pain intensity, number of oxycodone/acetaminophen combination medication used daily, 
number of bowel movements, and general weekly questions. Following this visit, Patient 
One was contacted by phone on Day 1 to begin the first two control weeks of the study 
by recording daily entries in the diaries. Patient One was contacted on Day 8 to ensure 
compliance, and then returned to the office with diaries of Weeks 1 & 2 to meet with the 
researcher on Day 15. At the appointment, the diaries were reviewed and the subject was 
given a sample pack for Namenda© and diaries for Weeks 3 & 4. Phone calls were made 
to address concerns and check compliance on Days 16 and 22. The patient was unable to 
attend the scheduled appointment on Day 29; the researcher picked up completed diaries 
and dropped off diaries for Weeks 5 & 6. Again, phone calls on Days 35 & 42 were made 
to address concerns and check compliance. The diaries for Weeks 5 & 6 were collected 
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by the researcher at the subject’s home due to inability to get to the scheduled 
appointment at the academic healthcare center. 
Based upon the collected diary data for Patient One (Figure 2), a small reduction 
of the daily averaged use of acetaminophen/oxycodone combination presents throughout 
the six weeks of the study (Figure 3 and Figure 4). 
 
Week Average Daily 
Percocet© Used 
Average Daily VAS 
Pain Intensity 
Average Number of 
Bowel Movements 
1 5.00 8.14 1.29 
2 4.43 8.05 0.86 
3 4.14 8.38 0.86 
4 4.29 9.00 1.14 
5 4.14 8.43 0.86 
6 4.71 8.57 0.86 
Figure 2. Averaged daily data per week including oxycodone/acetaminophen 
combination used (Percocet
©
 5mg/325mg), daily VAS pain scores, and number of bowel 
movements for Patient One. 
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Figure 3. Averaged daily number of acetaminophen/oxycodone combination medication 
for Patient One. 
 
 
Figure 4. Average daily number of acetaminophen/oxycodone combination medication 
on a weekly basis for Patient One. 
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Concurrently, there was a slight increase of daily averaged VAS pain scores from Week 3 
to Week 6 which appears to be in conflict with the reduction of daily 
acetaminophen/oxycodone combination intake. Moreover, Patient One recorded high 
VAS pain scores (9 or 10) every morning and evening throughout the six weeks of 
control and treatment phases of the study (Figure 5 and Figure 6).  
 
 
Figure 5. Average daily pain scores based off visual analogue scale (VAS) from 0-10. 
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Figure 6. Average daily pain scores based off visual analogue scale (VAS) on a weekly 
basis for Patient One. 
 
This data suggests that Patient One was not using the opioid medication properly for 
analgesia, or Patient One may have had a fear of addiction as a result of opioid use. As a 
result, no conclusion can be drawn about the reduction of acetaminophen/oxycodone 
combination use during these six weeks due to the corresponding increase of daily pain 
intensity, which may have resulted from the decrease in pain medication rather than the 
use of Namenda
©
.  Also, it is noted that the patient did not take the evening dosage of 
Namenda
©
 on Day 34 (5 mg) and Day 40 (10 mg), which may have disrupted the steady 
state of the medication.  Over the span of six weeks, there was no change in the daily 
number of bowel movements, thus no evidence in a reduction of constipation (Figure 7). 
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Figure 7. Daily number of bowel movements for Patient One. 
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DISCUSSION 
  
Clinical research is vital for advancing progress in both the practice of medicine 
and education of healthcare professionals. To understand the methodology and impact of 
human research, participation in the process of research design and application is 
important.  Gathering valid data from study patients can then be more efficiently 
translated from the scientific community to contribute to advances in medical practice. 
An academic healthcare center (AHC) is a potential outpatient setting where 
clinical research can be promoted. Clinical research remains an interactive and dynamic 
process between an AHC and academic institution (Figure 8). 
 
Figure 8. Clinical research interaction between AHC and institution. 
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Physicians in these AHCs see many patients and maintain direct contact with them. It is a 
collective community of healthcare professionals and patients which includes educating 
the next generation of physicians.  
Difficulties can arise when trying to implement research in this setting, especially 
in smaller AHCs.  Part of this is due to the lack ‘protected time’ for academic healthcare 
practitioners to participate in such endeavors apart from patient care and instruction of 
medical students, interns and residents. Therefore, research design must be appropriate 
for the demanding environment of an AHC; it needs to remain in harmony with 
community goals to inspire confidence and participation amongst the community.  
Recent experience conducting our small pilot investigational an AHC revealed a 
major obstacle to be patient compliance. Also, as a result of having no protected time for 
our physicians, recruitment of patients was negatively impacted.  
Our target patients were those with chronic low back pain who used daily an 
acetaminophen/oxycodone combination medication for analgesia on as-needed (prn) 
basis. Six patients were initially recruited but only one completed the study in the allotted 
time-frame for the investigation. 
 The challenge was to develop a study that correlated with community needs, i.e., 
those patients presenting with chronic low back pain who desired improved analgesia, 
and reduced opioid use. This patient population demographic seemed to be appropriate 
for the targeted AHC. Some participants were enthusiastic about contributing to a 
research project being conducted by their primary care physicians; they wanted to share 
their time and health history to help others. Those who were less enthusiastic usually had 
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other priorities or conflicts in life; some had demanding schedules which prevented 
compliance with the required office visits every two weeks while others did not pass the 
MMSE or GDS for inclusion. Two patients who completed all inclusion tests did 
complete the first two weeks (control period) of diaries and confirmed compliance when 
contacted by phone; however, they did not show up for their respective scheduled 
appointments at the AHC.  
From this experience, one recommendation would be to establish a group where 
patients can participate together in a supportive and educational setting. Since the patients 
involved with our study were receptive and appreciated sharing their stories of living 
with chronic pain, this approach may enhance recruitment. It would be beneficial for 
discussion and questions about the study, as well as provide a supportive environment of 
the shared experience. Through this experience, participants would benefit in collective 
motivation and guidance through a team-based approach to stay informed and maintain 
compliance. Group education can establish a dialogue in regards to clinical research 
studies involving a community; it would allow opportunity to a) explain informed 
consent, b) learn the schedule of data collection and office visits, c) address concerns of 
complications such as time and effort required to participate, and d) increase participant 
confidence in the process. In addition, by reaching out and discussing issues with the 
community, the AHC can educate about medical issues, research endeavors and answer 
questions about these issues. Patients may be more willing to participate in a clinical 
research study if it connects with their lives and community.  
Clinical research is hindered by many obstacles that present in an AHC where the 
environment is committed to providing health profession students with the experience of 
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the hands-on demands of direct patient care, as well as the exposure to day-to-day 
operations of medical practice and administration. On the whole, lack of trained clinical 
researchers in practice results from previous limitations to participate in research in these 
clinical settings, especially at smaller, less-funded educational institutions.  
Throughout the spectrum of healthcare professions, including medicine, nursing, 
dentistry, and pharmacy, the reduced amount of qualified clinical researchers results from 
discouraging factors such as lengthy training, lack of mentorship, and reduced potential 
salary compensations (Murillo, Reece, Snyderman, & Sung, 2006). Evidence-based 
medicine (EBM) remains a collaborative initiative to increase quality and efficacy in 
healthcare by sharing research insights of clinical research and decreasing the time for 
results to cause change in practice; by increasing protected time for experienced mentors 
to guide and train, investments can be made to increase the training experience at the 
AHC, and contribute to the quality of future clinical researchers (Murillo et al., 2006). 
Only through experience of research design and practice do future researchers gain 
hands-on application of knowledge; the AHC remains an excellent environment for 
investing in the training required to meet the demands in qualified researchers for future 
of clinical research endeavors.  
As a result of limited time for research investigations, as well as reduced 
availability of study participants and lack of funding, the burden of daily clinical and 
ethical responsibilities of physician investigators and researchers in an AHC can restrict 
implementation of quality research in the academic setting. A study published in 2001 
presents results from 478 surveys of department chairs and research administrators from 
medical schools in the United States and revealed that 93% regarded “pressure of faculty 
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to see patients” while simultaneously conducting clinical research as a moderate to large 
problem in academic investigational research; further, 48% reflected that the state of 
clinical research is not “healthy or robust” at their respective institutions (Campbell, 
Weissman, Moy, & Blumenthal, 2001). In addition to clinical pressures, respondents 
stated that identified major threats to clinical research to include reduced funding, 
inability to recruit experienced researchers, and competition from contract research 
organizations (CROs) (Campbell et al., 2001).  Overall, respondents regarded the quality 
of clinical research performed at their institutions to be inferior to nonclinical research 
and that there remains an “inadequate supply of trained clinical researchers” (Campbell et 
al., 2001). 
 The Clinical Research Rountable (CRR) of the Institute of Medicine was 
established in June 2000 as a multifaceted group of persons involved in clinical research 
who were responsible for addressing issues that affect the nation’s clinical research 
endeavors. In addition to identifying holistic challenges to clinical research such as 
inadequate funding, scarcity of experienced researchers, lack of public participation, and 
fragmented information systems, the CRR presented two major “translational blocks” 
that prevent the flow of information; first is the application of knowledge from the 
laboratory environment to human studies in the clinical setting, and second is the 
sequentially use of knowledge gained in the clinical environment to then be employed 
used in clinical practice (Sung et al., 2003). In 2004, the CRR proposed the establishment 
of the National Clinical Research Enterprise (NCRE) in 2004 in efforts to establish to 
provide  a  diverse public and private partnership in efforts to improve a national 
“outdated infrastructure” when it comes to regarding clinical research (Crowley et al., 
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2004). This initiative was proposed to be funded by 0.25% of the nation’s health care 
budget; the agenda would be to help to increase public education for understanding and 
participation in clinical research, provide training and assistance for researchers, improve 
technologies to share clinical research data, and fund clinical research efforts that support 
safety, efficiency, and validity (Crowley et al., 2004). Unfortunately, such proposed 
initiatives to create a system to address national clinical research concerns have not been 
realized; however, the AHC remains an essential setting to implement and advocate 
change. 
Benefits of increased clinical research in the primary care setting would include 
increased time and engagement between physician and patient, encourage involvement 
and participation in care, and perhaps allow access to newer treatments that are 
experimental and would otherwise not be available.   
Research design in practice must align with the daily operations of an AHC where 
both increased clinical hours of patient time and decreased protected time to engage in 
research activities restrict healthcare professionals from participating in research.  In our 
study, difficulties in recruiting patients were a result of physicians needing to identify 
patients from memory or being reminded of those that may be able to participate when 
acetaminophen/oxycodone combination prescriptions were refilled. With the help of the 
office manager and front desk staff at the AHC, the patient charts for potential recruits in 
our study were flagged to provide an additional reminder to the physicians to recruit. 
Through the implementation of advanced electronic medical records, software could 
assist to help physicians to identify potential recruits, flag their charts, and track their 
progress with increased efficiency.  
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The need for a commitment by academic medicine to focus on integration of 
different approaches of community-engaged research must be made as a progressive 
measure to increase the quality of healthcare experience by students and practitioners 
alike by involving patients more with their treatment and engaging them to participate in 
research that affects their community by addressing local concerns (Michener et al., 
2012). These researchers also stated that efforts must be made to a) educate the 
community about research endeavors, b) disseminate findings to the community, and c) 
to establish active involvement and participation from members of the community to 
promote clinical research in an AHC (Michener et al., 2012). Ultimately, the beneficiaries 
of clinical research are the participants and the public who receive care in a healthcare 
system. Initiatives to increase community education and involvement in the process will 
be at the foundation of the collaboration needed to continue pursuits of change. In our 
study, monetary compensation was a substantial motivation for participation amongst 
recruits. However, every recruit did share a psychological motivation though the sense of 
contribution. Attempts to increase community engagement have potential to cultivate 
community appreciation and increase likelihood of success in the clinical research 
process (Figure 9). 
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Figure 9. Including community engagement in the clinical research process. 
 
In many respects, clinical research in an AHC has the potential to gather vast 
amounts of knowledge that will not only contribute to increased wellness amongst a 
community, but will transcend beyond to national healthcare initiatives. By integrating 
appropriate research into medical practice, the physicians and patients can work together 
to answer questions in hopes of healing and wellness. Limited availability of primary care 
practitioners restricts the progression of clinical research in the AHC and beyond. 
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Strategies must be in place to develop, implement, and support clinical research. 
Hopefully, with advances in electronic records and web-based information systems, 
research can become more streamlined; efforts of increased staff teamwork will maintain 
coordination and efficiency of research endeavors to integrate research into primary care.  
Most importantly, research designs that acknowledge limitations of previous studies will 
support the academic environment to promote research in an AHC. At the level of the 
AHC, active discussion and debate among primary investigators, research investigators, 
faculty, staff, and students is vital for identifying complications and finding solutions 
throughout progression of the study. In many respects, AHC staff can provide valuable 
insight in regards to potential study patients and their ability to comply as a result of 
interactions of management, scheduling, billing, and general questions. By establishing a 
dialogue from the beginning amongst this the cooperative group of individuals at an 
AHC, strategies for recruitment and planning will increase efficiency and success of 
clinical research initiatives.  
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CONCLUSION 
 
This pilot study offered insight to the processes of developing a clinical research 
study and conducting a human investigation at an AHC.  It highlighted the need for 
institutional designation of sufficient ‘protected time’ for physicians and investigators in 
order for them to perform research in this setting. Only with adequate ‘protected time’ 
can investigators thoroughly participate in the process of design, recruitment, and 
completion of pilot investigational studies such as ours.   In addition, engagement of the 
AHC community, including physicians, students, staff, and the public they serve, is 
necessary to increase efforts for recruitment of study subjects. Participation for a clinical 
research study can also be increased through establishment of an educational dialogue.  
Clinical research must not be neglected in an environment such as the AHC since 
this setting promotes education and experience for the next generation of clinical 
researchers. The vitality of this next generation is of great concern. Only through active 
research development and implementation can future clinical researchers gain 
understanding of how a research process works. In addition, there will be an opportunity 
to determine how clinical research can be more efficient and transferred to improve 
medical care 
 Through exposure to clinical research, medical professionals will develop 
appreciation for the process; they will also obtain valuable training to enhance future 
endeavors in the progression of medicine. In this view, even failure to complete a 
research study offers guidance on how research design and practice can be improved, and 
identifies where further investments should be made. 
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 This study contributed to the education and training of those clinical investigators 
involved and shed light on limitations of design and institutional support. This experience 
served to highlight the importance and value of protected time for clinical researchers, 
especially in the educational environment of the AHC. The future of clinical research 
depends on investments made to increase protected time, engagement of the AHC 
community, and exposure to research training amongst health professional students. 
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Appendix B: Patient Diary: Week 1 (Front) 
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Appendix B: Patient Diary: Week 1 (Back) 
 
44 
 
Appendix C: Patient Diary: Week 2 (Front) 
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Appendix C: Patient Diary: Week 2 (Back) 
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Appendix D: Patient Diary: Week 3 (Front) 
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Appendix D: Patient Diary: Week 3 (Back) 
 
48 
 
Appendix E: Patient Diary: Week 4 (Front) 
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Appendix E: Patient Diary: Week 4 (Back) 
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Appendix F: Patient Diary: Week 5 (Front) 
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Appendix F: Patient Diary: Week 5 (Back) 
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Appendix G: Patient Diary: Week 6 (Front) 
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Appendix G: Patient Diary: Week 6 (Back) 
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Appendix H: Patient Study Schedule 
 
    
   
 
 
Memantine 
 
 
 
Pain 
 and 
 Medication 
Diary 
Visit to 
Roxborough 
Healthcare Center 
 
PART 1 
 
 
Week 1 None Daily   
    
Week 2 None Daily End of week 2 
     
PART 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Week 3 
 
5 mg Memantine  AM 
 - - - - - - - - - - - - - - - 
Nothing  PM 
Daily 
   
    
Week 4 
 
5 mg Memantine  AM 
                  + 
5 mg memantine  PM 
Daily 
 
 
End of week 4 
 
    
Week 5 
 
10 mg Memantine  AM 
                 + 
 5 mg memantine  PM 
Daily 
   
    
Week 6 
 
10 mg Memantine  AM  
                + 
10 mg memantine  PM 
Daily 
 
 
End of week 6 
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Appendix I: Short Form Geriatric Depression Scale Questionnaire 
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Appendix I: Short Form Geriatric Depression Scale Instructions 
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Appendix J: Mini Mental State Examination Questionnaire 
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Appendix J: Mini Mental State Examination Interpretation 
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